Pfizer Questions German Investment Future Over Price Reforms

In a letter dated June 9, Bourla outlined that the company is currently reassessing the scope, timing, and prioritization of its external engagements within the country. The executive cited the unpredictability created by legislative proposals aimed at curbing drug prices, which he claims complicates long-term capital allocation decisions for the firm.

This cooling of relations follows a pattern of corporate withdrawal across the sector. Eli Lilly recently halved a planned $2.3 billion investment, while Boehringer Ingelheim scrapped a €900 million project entirely. These decisions underscore a deepening friction between the German government and major pharmaceutical players over policies intended to balance the national budget at the expense of drug manufacturer revenue.